Developing the next generation of oncolytic immunotherapy.

Replimune, headquartered in Woburn, US with an R&D site in Oxford UK was founded in April 2015 to develop the next generation of "oncolytic immunotherapies" for the treatment of cancer. Replimune is developing a potent and versatile patient non-specific, universal neoantigen vaccination approach for the treatment of solid tumors, based on its Immulytic oncolytic immunotherapy platform."

  • CEO Robert Coffin
  • Industry Biotech